Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study

NCT07685704 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
HER2-positive Gastric Cancer

Interventions

DRUG: Zanidatamab
DRUG: Oxaliplatin
DRUG: Capecitabine
DRUG: S-1
DRUG: Tislelizumab

Sponsor

Zhifeng Zhao, PhD